Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting.
Title | Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Yavropoulou, M. P., Pikilidou M., Kotsa K., Michopoulos A., Papakonstantinou E., & Yovos J. G. |
Journal | J Diabetes Metab Disord |
Volume | 14 |
Pagination | 68 |
Date Published | 2015 |
ISSN | 2251-6581 |
Abstract | BACKGROUND: Inhibitors of dipeptidyl-peptidase IV are recommended as second-line therapy in type 2 diabetes (DT2), but data, as a first-line treatment in everyday clinical practice are scarce. To address this issue we conducted a 12-month, clinical study in an outpatient setting, using vildagliptin as the first-line treatment.METHODS: Ninety-one drug naïve patients with DT2 started with vildagliptin monotherapy (100 mg daily) for 4 months and were scheduled to regular 4-monthly visits for 1 year. Patients received add-on treatment with metformin or metformin and glimepiride according to their glycosylated hemoglobin (HbA1c) at each study-visit.RESULTS: HbA1c was significantly decreased with vildagliptin monotherapy from 8.16 % ± 1.60 to 7.52 % ± 1.60, p < 0.001. Only 39 % of the patients achieved the target of HbA1c ≤ 7.0 % at the end of the 4th month. Mean change in HbA1c was significantly correlated with baseline HbA1c values (r = -0.51, p < 0.001). At the end of the study only 35 % of the patients remained on vildagliptin monotherapy while the rest required add-on treatment with metformin or metformin and sulfonylurea.CONCLUSIONS: Vildagliptin is well tolerated either as monotherapy or in combination but the majority of patients require add-on therapy shortly after the beginning of treatment. |
DOI | 10.1186/s40200-015-0194-6 |
Alternate Journal | J Diabetes Metab Disord |
PubMed ID | 26355765 |
PubMed Central ID | PMC4563902 |